Amedisys, Inc. (NASDAQ:AMED) Shares Bought by Commonwealth Equity Services LLC

Commonwealth Equity Services LLC grew its stake in Amedisys, Inc. (NASDAQ:AMED) by 10.9% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 4,151 shares of the health services provider’s stock after buying an additional 409 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Amedisys were worth $381,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Banque Cantonale Vaudoise purchased a new stake in Amedisys in the first quarter valued at approximately $60,000. Innealta Capital LLC purchased a new stake in Amedisys during the second quarter worth $64,000. Covestor Ltd boosted its position in Amedisys by 134.2% during the first quarter. Covestor Ltd now owns 780 shares of the health services provider’s stock worth $72,000 after purchasing an additional 447 shares in the last quarter. Signaturefd LLC lifted its position in shares of Amedisys by 88.2% in the second quarter. Signaturefd LLC now owns 1,131 shares of the health services provider’s stock valued at $104,000 after acquiring an additional 530 shares in the last quarter. Finally, GAM Holding AG purchased a new stake in shares of Amedisys in the second quarter valued at $275,000. Hedge funds and other institutional investors own 94.36% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on AMED shares. William Blair downgraded Amedisys from an “outperform” rating to a “market perform” rating in a research report on Monday, July 1st. Cantor Fitzgerald reiterated a “neutral” rating and issued a $101.00 target price on shares of Amedisys in a research note on Thursday, July 25th. Finally, Deutsche Bank Aktiengesellschaft lowered Amedisys from a “buy” rating to a “hold” rating and set a $101.00 price objective for the company. in a research note on Monday, July 29th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $100.67.

Amedisys Stock Up 0.1 %

Shares of AMED stock opened at $97.30 on Monday. The business’s fifty day moving average is $97.69 and its 200-day moving average is $94.84. The stock has a market cap of $3.18 billion, a PE ratio of -152.03, a price-to-earnings-growth ratio of 1.89 and a beta of 0.78. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.16 and a current ratio of 1.16. Amedisys, Inc. has a 1 year low of $89.55 and a 1 year high of $98.95.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings results on Wednesday, July 24th. The health services provider reported $1.32 earnings per share for the quarter, beating the consensus estimate of $1.22 by $0.10. The firm had revenue of $591.19 million for the quarter, compared to analyst estimates of $579.34 million. Amedisys had a return on equity of 12.39% and a net margin of 4.02%. Equities analysts expect that Amedisys, Inc. will post 4.66 earnings per share for the current fiscal year.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.